卢丽姬,叶志龙,吴基炳,曾楚燕
LU Liji,YE Zhilong,WU Jibing,ZENG Chuyan

• 1:广州市海珠区瑞宝街社区卫生服务中心

摘要(Abstract)：

目的对比分析不同剂量美托洛尔治疗糖尿病合并冠心病的临床疗效。方法收集本院2010-1~2014-10期间诊治的188例糖尿病合并冠心病患者作为研究对象,所有患者均应用美托洛尔治疗,根据患者的不同用药剂量将患者分为大剂量组(剂量为25 mg,共计94例)和小剂量组(剂量为12.5 mg,共计94例)。观察2组患者持续治疗3个月后的心功能疗效情况、以及空腹血糖和餐后2 h血糖水平、血脂水平改善情况及不良反应发生情况。结果大剂量组与小剂量组患者在心功能疗效方面比较无明显差异(P>0.05),而大剂量组患者的空腹血糖和餐后2 h血糖、血脂改善水平明显优于小剂量组(P<0.05),2组患者治疗过程中均未出现明显不良反应。结论糖尿病合并冠心病患者应用大剂量美托洛尔治疗具有良好的临床效果,且不会明显增加不良反应。
OBJECTIVE To compared and analyze the clinical effects of different dose of metoprolol on patients with diabetes and coronary heart disease. METHODS A total of 188 patients with diabetes and coronary heart disease who were treated in the hospital from January,2010 to October,2014 were collected as the research objects,all patients were treated by metoprolol. According to the different doses,those patients were randomly divided into the large dose group( the dose of 25 mg,94 cases) and small dose group( the dose of 12. 5 mg,94 cases). Then,the duration of treatment effect of heart function after three months and the fasting blood glucose and postprandial 2 h blood glucose level and the improvement of blood lipid levels and the incidence of adverse reactions of these 2groups of patients were observed. RESULTS The effect of cardiac function between the large dose group and small dose group had no statistical significance( P > 0. 05),but the fasting blood glucose,2 h postprandial blood glucose and the improvement of blood glucose level in the large dose group were evidently better than that in the small dose group( P < 0. 05),and during treatment 2 groups of patients showed no obvious adverse reaction. CONCLUSION The clinical effects of diabetes mellitus with coronary heart disease cured by large dose of metoprolol are good enough,and will not significantly increase the adverse reaction.

关键词(KeyWords)： 美托洛尔;糖尿病;冠心病;临床疗效
metoprolol;diabetes mellitus;coronary heart;clinical effect

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 卢丽姬,叶志龙,吴基炳,曾楚燕
LU Liji,YE Zhilong,WU Jibing,ZENG Chuyan

参考文献(References)：

• [1]李晓苏,曲环,李美红,等.高选择性β1受体阻滞剂对冠心病合并血糖异常患者糖代谢的影响[J].中西医结合心脑血管病杂志,2012,10(5):538-538.
• [2]张惠琪,张进鹏,李自成,等.冠心病患者QT离散度与冠脉病变的关系及其干预治疗[J].暨南大学学报(自然科学与医学版),2011,32(4):426-429.
• [3]李东,赖晓惠.美托洛尔在糖尿病合并冠心病治疗中应用的效果观察[J].临床医药实践,2013,22(6):436-438.
• [4]扎依达·亚合甫江.β受体阻滞剂在糖尿病合并冠心病治疗中的应用研究[J].医学信息,2013,16(18):116-117.
• [5]陈斌.卡维地洛及美托洛尔对慢性心力衰竭合并糖尿病患者的心功能及胰岛素抵抗的影响[J].安徽医药,2010,14(1):94-96.
• [6]王晓焕,傅微,张云坤,等.β受体阻滞剂在冠心病合并糖尿病患者中的应用研究[J].中国老年保健医学,2013,11(3):27-28,30.
• [7]崔飞飞,徐惠.山莨菪碱联合美托洛尔治疗2型糖尿病合并慢性心力衰竭疗效观察[J].山东医药,2014,23(44):56-57.
• [8]陈文.培哚普利与美托洛尔治疗糖尿病无症状心功能不全的临床疗效比较[J].中国医师杂志,2013,15(4):559-561.